Amgen, Inc. (NASDAQ:AMGN) – Research analysts at Jefferies Group upped their FY2018 earnings estimates for Amgen in a report released on Wednesday, according to Zacks Investment Research. Jefferies Group analyst E. Yang now forecasts that the medical research company will earn $13.04 per share for the year, up from their prior estimate of $12.87. Jefferies Group has a “Hold” rating and a $180.00 price target on the stock.
Several other analysts have also issued reports on the company. Royal Bank of Canada set a $190.00 price objective on Amgen and gave the company a “buy” rating in a research note on Tuesday, January 31st. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 price objective on the stock in a research note on Monday, March 27th. Credit Suisse Group AG reaffirmed a “hold” rating and issued a $178.00 target price on shares of Amgen in a research report on Tuesday, April 4th. Bank of America Corp raised Amgen from a “neutral” rating to a “buy” rating and upped their target price for the company from $156.68 to $192.00 in a research report on Wednesday, February 1st. Finally, Mizuho set a $195.00 target price on Amgen and gave the company a “buy” rating in a research report on Thursday, March 16th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $187.84.
Shares of Amgen (NASDAQ:AMGN) traded up 0.053% on Friday, hitting $160.055. The company had a trading volume of 975,439 shares. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21. The firm has a 50 day moving average of $162.98 and a 200-day moving average of $158.52. The firm has a market capitalization of $117.70 billion, a P/E ratio of 15.203 and a beta of 1.15. Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.00 by $0.15. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The business had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the business earned $2.90 EPS. The firm’s revenue was down 1.1% compared to the same quarter last year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.88%. The ex-dividend date is Monday, May 15th. Amgen’s dividend payout ratio is currently 44.92%. Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in Amgen by 33.4% in the first quarter. FMR LLC now owns 54,412,531 shares of the medical research company’s stock valued at $8,927,464,000 after buying an additional 13,622,745 shares during the period. Vanguard Group Inc. raised its position in Amgen by 7.4% in the first quarter. Vanguard Group Inc. now owns 51,657,215 shares of the medical research company’s stock valued at $8,475,399,000 after buying an additional 3,560,566 shares during the period. BlackRock Inc. raised its position in Amgen by 2,265.0% in the first quarter. BlackRock Inc. now owns 48,541,514 shares of the medical research company’s stock valued at $7,964,207,000 after buying an additional 46,489,004 shares during the period. State Street Corp raised its position in Amgen by 2.8% in the fourth quarter. State Street Corp now owns 34,308,673 shares of the medical research company’s stock valued at $5,016,268,000 after buying an additional 919,966 shares during the period. Finally, BlackRock Fund Advisors raised its position in Amgen by 1.1% in the third quarter. BlackRock Fund Advisors now owns 13,112,904 shares of the medical research company’s stock valued at $2,187,364,000 after buying an additional 141,076 shares during the period. 79.04% of the stock is owned by institutional investors and hedge funds.
About Amgen Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Get a free copy of the Zacks research report on Amgen (AMGN) For more information about research offerings from Zacks Investment Research, visit Zacks.com